You have free access to this content

New prognostic factors of cutaneous melanoma: a review of the literature

  1. Ning Li,
  2. Janine Mangini,
  3. Jag Bhawan

Article first published online: 19 JUL 2002

DOI: 10.1034/j.1600-0560.2002.290602.x

Issue

Journal of Cutaneous Pathology

Journal of Cutaneous Pathology

Volume 29, Issue 6, pages 324–340, July 2002

Additional Information

How to Cite

Li, N., Mangini, J. and Bhawan, J. (2002), New prognostic factors of cutaneous melanoma: a review of the literature. Journal of Cutaneous Pathology, 29: 324–340. doi: 10.1034/j.1600-0560.2002.290602.x

Author Information

  1. Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA

*Jag Bhawan MD, 609 Albany St, J-309, Boston, MA, 02118, USA Tel: +1-617-638-5570 Fax: +1-617-638-5575 e-mail: jbhawan@bu.edu

Publication History

  1. Issue published online: 19 JUL 2002
  2. Article first published online: 19 JUL 2002
  3. Accepted October 27, 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (129K)

References

  • 1
    Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705.
  • 2
    Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17: 443.
  • 3
    Byers HR, Bhawan J. Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Hematol Oncol Clin North Am 1998; 12: 717.
  • 4
    Ackerman AB. Disagreements about classification of malignant melanomas. Am J Dermatopathol 1982; 4: 447.
  • 5
    Guerry Dt Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression. the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993; 100: 342S.
  • 6
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902.
  • 7
    Clark WH Jr, Elder DE, Guerry DT et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893.
  • 8
    Schuchter L, Schultz DJ, Synnestvedt M et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 1996; 125: 369.
  • 9
    Leon P, Daly JM, Synnestvedt M et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126: 1461.
  • 10
    Sahin S, Rao B, Kopf AW et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997; 80: 1426.
  • 11
    Berdeaux DH, Meyskens FL Jr et al. Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease. Cancer 1989; 63: 1430.
  • 12
    Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and clark level in melanoma. support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 2000; 88: 589.DOI: 10.1002/(sici)1097-0142(20000201)88:3<589::aid-cncr15>3.0.co;2-i
  • 13
    Rigel DS, Friedman RJ, Kopf AW, Silverman MK. Factors influencing survival in melanoma. Dermatol Clin 1991; 9: 631.
  • 14
    Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal ‘thin’ malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208: 150.
  • 15
    Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors. relation to probability of metastatic dissemination and long-term survival. Radiother Oncol 1989; 15: 1.
  • 16
    Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489.
  • 17
    Korabiowska M, Brinck U, Middel P et al. Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res 2000; 20: 1781.
  • 18
    Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995; 105: 22.
  • 19
    Boni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996; 35: 416.
  • 20
    Vogt T, Zipperer KH, Vogt A et al. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57.
  • 21
    Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6: 1845.
  • 22
    Henrique R, Azevedo R, Bento MJ et al. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000; 43: 991.
  • 23
    Reddy VB, Gattuso P, Aranha G, Carson HJ. Cell proliferation markers in predicting metastasis in malignant melanoma. J Cutan Pathol 1995; 22: 248.
  • 24
    Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 1996; 23: 335.
  • 25
    Kanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1997; 10: 917.
  • 26
    Kaleem Z, Lind AC, Humphrey PA et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol 2000; 13: 217.
  • 27
    Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995; 8: 530.
  • 28
    Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res 1995; 287: 146.
  • 29
    Saenz-Santamaria MC, McNutt NS, Bogdany JK, Shea CR. p53 expression is rare in cutaneous melanomas. Am J Dermatopathol 1995; 17: 344.
  • 30
    Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995; 133: 23.
  • 31
    Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999; 85: 375.
  • 32
    Piepkorn M. Melanoma genetics. an update with focus on the CDKN2A (p16) /ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705 (quiz 23).
  • 33
    Funk JO, Schiller PI, Barrett MT et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291.
  • 34
    Kumar R, Lundh Rozell B, Louhelainen J, Hemminki K. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 1998; 75: 193.
  • 35
    Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998; 110: 932.
  • 36
    Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255.
  • 37
    Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74: 255.
  • 38
    Reed JA, Loganzo F Jr, Shea CR et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713.
  • 39
    Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997; 74: 535.DOI: 10.1002/(sici)1097-0215(19971021)74:5<535::aid-ijc10>3.3.co;2-1
  • 40
    Grover R, Chana JS, Wilson GD, Richman PI, Sanders R. An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res 1998; 8: 267.
  • 41
    Bales ES, Dietrich C, Bandyopadhyay D et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113: 1039.
  • 42
    Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000; 6: 3614.
  • 43
    Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10: 775.
  • 44
    Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44.
  • 45
    Riou GF. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv 1988; 7: 441.
  • 46
    Field JK, Spandidos DA, Stell PM et al. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463.
  • 47
    Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg 1998; 85: 46.
  • 48
    Grover R, Grobbelaar AO, Hudson DA et al. The clinical significance of oncogene expression in subungual melanoma. Br J Plast Surg 1997; 50: 15.
  • 49
    Grover R, Chana J, Grobbelaar AO et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg 1999; 52: 122.DOI: 10.1054/bjps.1998.3024
  • 50
    Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997; 50: 478.
  • 51
    Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426: 461.
  • 52
    Boni R, Bantschapp O, Muller B, Burg G. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma. Dermatology 1998; 196: 288.
  • 53
    Reuning U, Magdolen V, Wilhelm O et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893.
  • 54
    Ferrier CM, Suciu S, Van Geloof WL et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 2000; 83: 1351.
  • 55
    Ferrier CM, Van Muijen GN, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998; 30: 431.
  • 56
    De Vries TJ, Quax PH, Denijn M et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70.
  • 57
    Delbaldo C, Masouye I, Saurat JH, Vassalli JD, Sappino AP. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994; 54: 4547.
  • 58
    Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115: 337.DOI: 10.1046/j.1523-1747.2000.00068.x
  • 59
    Airola K, Karonen T, Vaalamo M et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733.
  • 60
    Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283.
  • 61
    Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51.
  • 62
    Hofmann UB, Westphal JR, Zendman AJ et al. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191: 245.DOI: 10.1002/1096-9896(2000)9999:9999<::aid-path632>3.3.co;2-r
  • 63
    Van Den Oord JJ, Paemen L, Opdenakker G, De Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665.
  • 64
    Hieken TJ, Ronan SG, Farolan M et al. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastasis. Surgery 1995; 118: 669 (discussion, p. 73).
  • 65
    Seftor RE. Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha (v) beta3 integrin expression. Am J Pathol 1998; 153: 1347.
  • 66
    Van Belle PA, Elenitsas R, Satyamoorthy K et al. Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999; 30: 562.
  • 67
    Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R, Bigotti A. Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer 1993; 54: 68.
  • 68
    Vihinen P, Nikkola J, Vlaykova T et al. Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res 2000; 10: 243.
  • 69
    Kageshita T, Hamby CV, Hirai S et al. Differential clinical significance of alpha (v) Beta (3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 2000; 89: 153.DOI: 10.1002/(sici)1097-0215(20000320)89:2<153::aid-ijc9>3.3.co;2-t
  • 70
    Hofmann UB, Westphal JR, Waas ET et al. Coexpression of integrin alpha (v) beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 2000; 115: 625.DOI: 10.1046/j.1523-1747.2000.00114.x
  • 71
    Natali PG, Hamby CV, Felding-Habermann B et al. Clinical significance of alpha (v) beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997; 57: 1554.
  • 72
    Sy MS, Mori H, Liu D. CD44 as a marker in human cancers. Curr Opin Oncol 1997; 9: 108.
  • 73
    Manten-Horst E, Danen EH, Smit L et al. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 1995; 64: 182.
  • 74
    Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol 1996; 135: 876.
  • 75
    Schaider H, Soyer HP, Heider KH et al. CD44 and variants in melanocytic skin neoplasms. J Cutan Pathol 1998; 25: 199.
  • 76
    Seelentag WK, Boni R, Gunthert U et al. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential. J Cutan Pathol 1997; 24: 206.
  • 77
    Karjalainen JM, Tammi RH, Tammi MI et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000; 157: 957.
  • 78
    Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997; 33: 926.
  • 79
    Xie S, Luca M, Huang S et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57: 2295.
  • 80
    Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146) -specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 1998; 11: 1098.
  • 81
    Kraus A, Masat L, Johnson JP. Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen. Melanoma Res 1997; 7: S75.
  • 82
    Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994; 54: 2514.
  • 83
    Natali P, Nicotra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271.
  • 84
    Ciotti P, Pesce GP, Cafiero F et al. Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma Res 1999; 9: 253.
  • 85
    Danen EH, De Vries TJ, Morandini R et al. E-cadherin expression in human melanoma. Melanoma Res 1996; 6: 127.
  • 86
    Silye R, Karayiannakis AJ, Syrigos KN et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998; 186: 350.
  • 87
    Smith KJ, Germain M, Skelton H. Perspectives in dermatopathology. telomeres and telomerase in ageing and cancer; with emphasis on cutaneous disease. J Cutan Pathol 2000; 27: 2.
  • 88
    Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011.
  • 89
    Glaessl A, Bosserhoff AK, Buettner R et al. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 1999; 291: 81.DOI: 10.1007/s004030050387
  • 90
    Rudolph P, Schubert C, Tamm S et al. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol 2000; 156: 1425.
  • 91
    Miracco C, Pacenti L, Santopietro R et al. Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum Pathol 2000; 31: 1018.
  • 92
    Yang P, Becker D. Telomerase activity and expression of apoptosis and anti-apoptosis regulators in the progression pathway of human melanoma. Int J Oncol 2000; 17: 913.
  • 93
    Ramirez RD, D'Atri S, Pagani E et al. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia 1999; 1: 42.
  • 94
    King R, Weilbaecher KN, McGill G et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999; 155: 731.
  • 95
    King R, Googe PB, Weilbaecher KN, Mihm MC Jr, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25: 51.
  • 96
    Koch MB, Shih IM, Weiss SW, Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am J Surg Pathol 2001; 25: 58.
  • 97
    Salti GI, Manougian T, Farolan M et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000; 60: 5012.
  • 98
    Boukerche H, Baril P, Tabone E et al. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype. Cancer Res 2000; 60: 5848.
  • 99
    Kaskel P, Berking C, Sander S et al. S-100 protein in peripheral blood: a marker for melanoma metastasis: a prospective 2-center study of 570 patients with melanoma. J Am Acad Dermatol 1999; 41: 962.
  • 100
    Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143: 269.
  • 101
    Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998; 138: 426.DOI: 10.1046/j.1365-2133.1998.02119.x
  • 102
    Berking C, Schlupen EM, Schrader A, Atzpodien J, Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res 1999; 291: 479.DOI: 10.1007/s004030050441
  • 103
    Banfalvi T, Gilde K, Boldizsar M, Kremmer T, Otto S. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res 1999; 5: 218.
  • 104
    Hauschild A, Michaelsen J, Brenner W et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999; 9: 155.
  • 105
    Wagner V, Rudi J, Naher H, Stremmel W. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Med Oncol 2000; 17: 35.
  • 106
    Deichmann M, Benner A, Bock M et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891.
  • 107
    Banfalvi T, Gilde K, Boldizsar M et al. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 2000; 30: 900.
  • 108
    Bonfrer JM, Korse CM. Monitoring malignant melanoma with the S-100B tumour marker. Recent Results Cancer Res 2001; 158: 149.
  • 109
    Hauschild A, Engel G, Brenner W et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140: 1065.DOI: 10.1046/j.1365-2133.1999.02905.x
  • 110
    Apfel R, Lottspeich F, et al. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 1992; 2: 327.
  • 111
    Bosserhoff AK, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996; 271: 490.
  • 112
    Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149.
  • 113
    Bosserhoff AK, Dreau D, Hein R et al. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results Cancer Res 2001; 158: 158.
  • 114
    Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20: 2203.
  • 115
    Juergensen A, Holzapfel U, Hein R et al. Comparison of two prognostic markers for malignant melanoma. MIA S100 Beta Tumour Biol 2001; 22: 54.
  • 116
    Wibe E, Hannisdal E, Paus E, Aamdal S. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur J Cancer 1992; 28A: 1692.
  • 117
    Buzaid AC, Sandler AB, Hayden CL et al. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 1994; 17: 430.
  • 118
    Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ. The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 1992; 28: 55.
  • 119
    Miliotes G, Lyman GH, Cruse CW et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996; 3: 558.
  • 120
    Karnell R, Kagedal B, Lindholm C et al. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000; 10: 363.DOI: 10.1097/00008390-200008000-00008
  • 121
    Hirai S, Kageshita T, Kimura T et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 1997; 7: 58.
  • 122
    Wimmer I, Meyer JC, Seifert B et al. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073.
  • 123
    Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629.
  • 124
    Karnell R, Von Schoultz E, Hansson LO et al. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 1997; 7: 393.
  • 125
    Hasegawa M, Takata M, Hatta N et al. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 1997; 7: 243.
  • 126
    Franzke A, Probst-Kepper M, Buer J et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998; 78: 40.
  • 127
    Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995; 5: 179.
  • 128
    Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000; 83: 847.
  • 129
    Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997; 108: 166.
  • 130
    Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054ss.
  • 131
    Palmieri G, Strazzullo M, Ascierto PA et al. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999; 17: 304.
  • 132
    Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109.
  • 133
    Glaser R, Rass K, Seiter et al. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 1997; 15: 2818.
  • 134
    Farthmann B, Eberle J, Krasagakis K et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 1998; 110: 263.DOI: 10.1046/j.1523-1747.1998.00131.x
  • 135
    Keilholz U, Willhauck M, Rimoldi D et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR) -based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 1998; 34: 750.
  • 136
    Brossart P, Keilholz U, Willhauck M et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993; 101: 887.
  • 137
    Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16: 1760.
  • 138
    Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999; 141: 30.
  • 139
    Schrader AJ, Probst-Kepper M, Grosse J et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res 2000; 10: 355.DOI: 10.1097/00008390-200008000-00007
  • 140
    Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastasis. J Clin Oncol 1999; 17: 2562.
  • 141
    Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227.
  • 142
    Battayani Z, Grob JJ, Xerri L et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995; 131: 443.
  • 143
    Foss AJ, Guille MJ, Occleston NL et al. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995; 72: 155.
  • 144
    Kunter U, Buer J, Probst M et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996; 88: 590.
  • 145
    Proebstle TM, Jiang W, Hogel J et al. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 2000; 82: 118.
  • 146
    Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996; 14: 2091.
  • 147
    Aubin F, Chtourou M, Teyssier JR et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000; 10: 113.
  • 148
    Mellado B, Gutierrez L, Castel T et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999; 5: 1843.
  • 149
    Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000; 60: 2253.
  • 150
    Buzaid AC, Tinoco LA, Jendiroba D et al. Prognostic value of size of lymph node metastasis in patients with cutaneous melanoma. J Clin Oncol 1995; 13: 2361.
  • 151
    Baisden BL, Askin FB, Lange JR, Westra WH. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastasis in patients with melanoma. Am J Surg Pathol 2000; 24: 1140.DOI: 10.1097/00000478-200008000-00012
  • 152
    Blaheta HJ, Ellwanger U, Schittek B et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114: 637.
  • 153
    Bostick PJ, Morton DL, Turner RR et al. Prognostic significance of occult metastasis detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238.
  • 154
    Li W, Stall A, Shivers SC et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231: 795.DOI: 10.1097/00000658-200006000-00003
  • 155
    Wang X, Heller R, VanVoorhis N et al. Detection of submicroscopic lymph node metastasis with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220: 768.
  • 156
    Blaheta HJ, Schittek B, Breuninger H et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999; 23: 822.
  • 157
    Lukowsky A, Bellmann B, Ringk A et al. Detection of melanoma micrometastasis in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol 1999; 113: 554.DOI: 10.1046/j.1523-1747.1999.00719.x
  • 158
    Shivers SC, Wang X, Li W et al. Molecular staging of malignant melanoma: correlation with clinical outcome. Jama 1998; 280: 1410.
  • 159
    Blaheta HJ, Schittek B, Breuninger H et al. Lymph node micrometastasis of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998; 79: 318.
  • 160
    Carson KF, Wen DR, Li PX et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996; 20: 834.DOI: 10.1097/00000478-199607000-00006
  • 161
    Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994; 102: 102.
  • 162
    Calogero A, Timmer-Bosscha H, Schraffordt Koops H et al. Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastasis in lymph nodes. Br J Cancer 2000; 83: 184.DOI: 10.1054/bjoc.2000.1282
  • 163
    Van Der Velde-Zimmermann D, Schipper ME, De Weger RA, Hennipman A, Borel Rinkes IH. Sentinel node biopsies in melanoma patients. a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000; 7: 51.
View Full Article (HTML) Get PDF (129K)